Evidence map›Paper›PMID 32995094›Full record

ArticlePeerJ2020

Cocoa colonic phenolic metabolites are related to HDL-cholesterol raising effects and methylxanthine metabolites and insoluble dietary fibre to anti-inflammatory and hypoglycemic effects in humans.

Beatriz Sarriá, Miren Gomez-Juaristi, Sara Martínez López, Joaquín García Cordero, Laura Bravo, Mª Raquel Mateos Briz

Open access · goldAbstract read
In one paragraph

Article in PeerJ, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Investigating the Underlying Mechanisms ofMolecules (Basel, Switzerland) · 2023
    Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Beatriz SarriáDepartment of Metabolism and Nutrition, Institute of Food Science, Technology and Nutrition (ICTAN-CSIC); Spanish National Research Council (CSIC), Madrid, Spain.
Miren Gomez-JuaristiDepartment of Metabolism and Nutrition, Institute of Food Science, Technology and Nutrition (ICTAN-CSIC); Spanish National Research Council (CSIC), Madrid, Spain.
Sara Martínez LópezDepartment of Metabolism and Nutrition, Institute of Food Science, Technology and Nutrition (ICTAN-CSIC); Spanish National Research Council (CSIC), Madrid, Spain.
Joaquín García CorderoDepartment of Metabolism and Nutrition, Institute of Food Science, Technology and Nutrition (ICTAN-CSIC); Spanish National Research Council (CSIC), Madrid, Spain.
Laura BravoDepartment of Metabolism and Nutrition, Institute of Food Science, Technology and Nutrition (ICTAN-CSIC); Spanish National Research Council (CSIC), Madrid, Spain.
Mª Raquel Mateos BrizDepartment of Metabolism and Nutrition, Institute of Food Science, Technology and Nutrition (ICTAN-CSIC); Spanish National Research Council (CSIC), Madrid, Spain.
National Research Council · LK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn many cocoa intervention studies, health outcomes are related to cocoa components without taking into account the bioavailability of the main bioactive components: phenolic compounds and methylxanthines.

methodsThe present work associates the results of bioavailability and randomised controlled crossover studies in humans carried out with similar cocoa products, so that the main phenol and methylxanthine metabolites observed in plasma and urine are associated to the health effects observed in the chronic studies. We outstand that doses of cocoa and consumption rate used are realistic. In the bioavailability study, a conventional (CC) and a methylxanthine-polyphenol rich (MPC) cocoa product were used, whereas in the chronic study a dietary fibre-rich (DFC) and a polyphenol-rich (PC) product were studied in healthy and cardiovascular risk subjects. RESULTS AND DISCUSSION: The main phenolic metabolites formed after CC and MPC intake, 5-(4'-hydroxyphenyl)-γ-valerolactone-3'-sulfate, 3'-methyl-epicatechin-5-sulfate, 4-hydroxy-5-(4'-hydroxyphenyl)valeric acid-sulfate, 5-phenyl-γ-valerolactone--sulfate and 5-(4'-hydroxyphenyl)-γ-valerolactone-3'-glucuronide, may contribute to the changes in cholesterol (and indirectly HDL-cholesterol) observed after the regular intake of both DFC and PC, in healthy and cardiovascular risk subjects, whereas 7-methylxanthine (the main cocoa methylxanthine metabolite) and theobromine, together with its content in insoluble dietary fibre, may be responsible for the decrease of IL-1β and hypoglycemic effects observed with DFC. With both phenolic and methylxanthine metabolites a strong dose-response effect was observed.

conclusionAfter the regular consumption of both DFC and PC, positive changes were observed in volunteer's lipid profile, which may be related to the long-lasting presence of colonic phenolic metabolites in blood. In contrast, the anti-inflammatory and hypoglycemic effects were only observed with DFC, and these may be related to methylxanthine metabolites, and it is likely that insoluble dietary fibre may have also played a role.

Indexed as

Cardiovascular healthCocoaEpicatechinFlavanolsGlucoseHDL-cholesterolHumansMethylxanthinesTheobromine

Identifiers

PMID32995094
PMCPMC7502235
OpenAlexW3088955710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.